DIA Biosimilars 2013

Ferrer

Lorediplon has best-in-class results for insomnia

Friday, February 10, 2012 03:38 PM

Ferrer, a privately-held Spanish pharmaceutical company, has released results from a phase I trial of Lorediplon in insomnia showing it has a best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to market leader zolpidem.

More... »

Cenduit: Now with Patient Reminders

Ferrer begins phase III trial of Ozenoxacin for skin conditions

Saturday, January 21, 2012 01:12 PM

Ferrer, a privately-held Spanish pharmaceutical company, has received approval to initiate phase III clinical trials of ozenoxacin formulated as a topical treatment for infectious dermatological conditions. The first patients are expected to enter the trials in February 2012 and the studies are scheduled to conclude in the first quarter of 2013.

The randomized, placebo-controlled, parallel, double-blinded, superiority clinical study will compare ozenoxacin 1% cream versus a placebo. The trial will be conducted in about 465 patients up to two years old with a clinical diagnosis of non-bullous or bullous impetigo. Fifty centers will be participating in the study in the U.S., South Africa, Germany, Romania, India and Ukraine.

More... »

CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.